Revised SPCs: Imbruvica (ibrutinib) film-coated tablets – all strengths
SPCs updated to warn of cases of haemophagocytic lymphohistiocytosis in patients treated with ibrutinib; and splenic rupture following discontinuation of treatment. Also, now recommends patients should be monitored for signs and symptoms of cardiac failure during treatment.
Source:
electronic Medicines compendium